Z51.1
Sponsors
Bristol-Myers Squibb
Conditions
Advanced Endometrial CancerAdvanced Hepatocellular CarcinomaCastration-Resistant Prostate CancerPh+ LeukemiaRecurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology
Phase 2
A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology
RecruitingRBR-48pb9h
Start: 2010-07-01Updated: 2025-10-27
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemia
with Resistance or Intolerance to Imatinib
RecruitingRBR-5hzmjx
Start: 2010-03-01Updated: 2025-10-27
Phase 3
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with
Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer
Active, not recruitingRBR-36w269
Start: 2010-01-01Updated: 2025-10-27
A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel Or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy
RecruitingRBR-7spw98
Start: 2010-03-01Updated: 2025-10-27
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma
RecruitingRBR-84sdd6
Start: 2010-05-01Updated: 2025-10-27
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best
Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced
Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib
Active, not recruitingRBR-28gdtz
Start: 2010-02-01Updated: 2025-10-27